Ronald de Wit

Add links
From Wikipedia, the free encyclopedia

Ronald de Wit is a professor of medical oncology at Erasmus University Medical Center in Rotterdam, Netherlands. He is the founding chairman of the Dutch Uro-Oncology Study Group (DUOS).[1][2]

Early life and education[edit]

Ronald de Wit was born on August 8, 1955, in Amsterdam. He earned his MD from the University of Amsterdam and became a Registered Specialist in Internal Medicine. In 1990, he completed his training in Medical Oncology and earned his PhD on the topic "Treatment Aspects of AIDS-associated Kaposi’s Sarcoma" from the University of Amsterdam.[3]

Research and career[edit]

Ronald de Wit has been the lead investigator or senior author on numerous trials related to germ cell cancer.[4][5][6] One trial demonstrated that three cycles of BEP were an adequate treatment for good-risk metastatic disease.[7][8] One of his research projects identified docetaxel as an effective treatment for castrate-resistant prostate cancer.[9][10] A contribution from this period was the publication of the CARD trial in the New England Journal of Medicine in 2019.[11][12]

Currently, his research encompasses both clinical and translational studies, focusing on the interplay between taxanes and the latest hormonal agents, as well as biomarker investigations.[13][14] He is also affiliated with the Research Unit for Translational Pharmacology in the Department of Medical Oncology at Erasmus University Medical Center.[15][16]

During the 2010s, he participated in industry-led immunotherapy trials concerning Checkpoint Inhibitors. These trials paved the way for the approval of Pembrolizumab in both second and first-line treatments, including for non-muscle invasive diseases. His contributions extend to translational and immuno-oncology research, specifically on biomarker studies that determine prognostic and predictive factors for checkpoint inhibition.[17][18]

In addition to his contributions in the treatment of urological cancers, Ronald de Wit has been involved in advancing the management of chemotherapy-induced nausea and vomiting. He introduced a statistical method that revealed the diminishing efficacy of 5HT3 Receptor antagonists as antiemetic treatment over consecutive cycles of therapy, primarily due to their inability to manage delayed nausea effectively. Furthermore, he played a role in the development and subsequent FDA and EMA approval of the NK1 antagonist, aprepitant.[19] His research highlighted that when 5HT3 and NK1 drugs are used in combination, they offer considerably enhanced efficacy throughout multiple cycles due to improved control over delayed nausea and emesis.[20]

Selected publications[edit]

  • Ronald de Wit, Stephen J. Freedland, Stephane Oudard, Georgi Marinov, Philippe Capart, Austin J. Combest, Ryan Peterson, Ayse Ozatilgan, and Alicia K. Morgans. Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD.[21]
  • Ronald de Wit, Thomas Powles, Daniel Castellano, Andrea Necchi, Jae-Lyun Lee, Michiel S. van der Heijden, Nobuaki Matsubara, Aristotelis Bamias, Aude Fléchon, Cora N. Sternberg, Alexandra Drakaki, Evan Y. Yu, Annamaria H. Zimmermann, Amanda Long, Richard A. Walgren, Ling Gao, Katherine M. Bell-McGuinn, and Daniel P. Petrylak. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.[22]
  • Ronald de Wit, Bertrand Tombal, and Stephen Freedland. Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer.
  • Ronald de Wit. Refinement of the Management of Germ Cell Cancer: What’s Next?.[23]
  • Ronald de Wit, Johann de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean-Christophe Eymard, Aristotelis Bamias, Joan Carles, and Roberto Iacovelli. Bohuslav MelicharCabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.[24]

External links[edit]

References[edit]

  1. ^ "TRANSCRIPT: 040721 - Ronald de Wit: ESMO CARD 3rd line treatment". www.urotoday.com. Retrieved 2023-06-13.
  2. ^ "Dutch Uro- Oncology Studygroup (DUOS)". Stichting DUOS (in Dutch). Retrieved 2023-06-13.
  3. ^ "Ronald de Wit". facultyopinions.com. Retrieved 2023-06-13.
  4. ^ de Wit, R.; Stoter, G.; Sleijfer, D. T.; Kaye, S. B.; de Mulder, P. H.; ten Bokkel Huinink, W. W.; Spaander, P. J.; de Pauw, M.; Sylvester, R. (June 1995). "Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group". British Journal of Cancer. 71 (6): 1311–1314. doi:10.1038/bjc.1995.254. ISSN 0007-0920. PMC 2033818. PMID 7540039.
  5. ^ de Wit, R.; Sylvester, R.; Tsitsa, C.; de Mulder, P. H. M.; Sleyfer, D. T.; ten Bokkel Huinink, W. W.; Kaye, S. B.; van Oosterom, A. T.; Boven, E.; Vermeylen, K.; Stoter, G. (February 1997). "Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer". British Journal of Cancer. 75 (3): 432–435. doi:10.1038/bjc.1997.71. ISSN 1532-1827. PMC 2063372. PMID 9020492.
  6. ^ de Wit, R; Stoter, G; Kaye, S B; Sleijfer, D T; Jones, W G; ten Bokkel Huinink, W W; Rea, L A; Collette, L; Sylvester, R (May 1997). "Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group". Journal of Clinical Oncology. 15 (5): 1837–1843. doi:10.1200/JCO.1997.15.5.1837. ISSN 0732-183X. PMID 9164193.
  7. ^ de Wit, Ronald (December 1999). "Treatment of disseminated non-seminomatous testicular cancer: The European experience". Seminars in Surgical Oncology. 17 (4): 250–256. doi:10.1002/(SICI)1098-2388(199912)17:4<250::AID-SSU5>3.0.CO;2-M. ISSN 8756-0437. PMID 10588853.
  8. ^ de Wit, Ronald; Fizazi, Karim (2006-12-10). "Controversies in the Management of Clinical Stage I Testis Cancer". Journal of Clinical Oncology. 24 (35): 5482–5492. doi:10.1200/JCO.2006.07.9434. ISSN 0732-183X. PMID 17158533.
  9. ^ Scher, Howard I.; Fizazi, Karim; Saad, Fred; Taplin, Mary-Ellen; Sternberg, Cora N.; Miller, Kurt; de Wit, Ronald; Mulders, Peter; Chi, Kim N.; Shore, Neal D.; Armstrong, Andrew J.; Flaig, Thomas W.; Fléchon, Aude; Mainwaring, Paul; Fleming, Mark (2012-09-27). "Increased survival with enzalutamide in prostate cancer after chemotherapy". The New England Journal of Medicine. 367 (13): 1187–1197. doi:10.1056/NEJMoa1207506. hdl:2066/108324. ISSN 1533-4406. PMID 22894553.
  10. ^ Saad, Fred; Fizazi, Karim; Jinga, Viorel; Efstathiou, Eleni; Fong, Peter C.; Hart, Lowell L.; Jones, Robert; McDermott, Raymond; Wirth, Manfred; Suzuki, Kazuhiro; MacLean, David B.; Wang, Ling; Akaza, Hideyuki; Nelson, Joel; Scher, Howard I. (March 2015). "Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial". The Lancet. Oncology. 16 (3): 338–348. doi:10.1016/S1470-2045(15)70027-6. ISSN 1474-5488. PMID 25701170.
  11. ^ de Wit, Ronald; de Bono, Johann; Sternberg, Cora N.; Fizazi, Karim; Tombal, Bertrand; Wülfing, Christian; Kramer, Gero; Eymard, Jean-Christophe; Bamias, Aristotelis; Carles, Joan; Iacovelli, Roberto; Melichar, Bohuslav; Sverrisdóttir, Ásgerður; Theodore, Christine; Feyerabend, Susan (2019-12-26). "Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer". The New England Journal of Medicine. 381 (26): 2506–2518. doi:10.1056/NEJMoa1911206. hdl:2066/215761. ISSN 1533-4406. PMID 31566937.
  12. ^ Fizazi, Karim; Kramer, Gero; Eymard, Jean-Christophe; Sternberg, Cora N.; de Bono, Johann; Castellano, Daniel; Tombal, Bertrand; Wülfing, Christian; Liontos, Michael; Carles, Joan; Iacovelli, Roberto; Melichar, Bohuslav; Sverrisdóttir, Ásgerður; Theodore, Christine; Feyerabend, Susan (November 2020). "Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study". The Lancet. Oncology. 21 (11): 1513–1525. doi:10.1016/S1470-2045(20)30449-6. ISSN 1474-5488. PMID 32926841.
  13. ^ van Soest, R. J.; van Royen, M. E.; de Morrée, E. S.; Moll, J. M.; Teubel, W.; Wiemer, E. a. C.; Mathijssen, R. H. J.; de Wit, R.; van Weerden, W. M. (December 2013). "Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer". European Journal of Cancer. 49 (18): 3821–3830. doi:10.1016/j.ejca.2013.09.026. ISSN 1879-0852. PMID 24200698.
  14. ^ van Soest, Robert J.; de Morrée, Ellen S.; Kweldam, Charlotte F.; de Ridder, Corrina M. A.; Wiemer, Erik A. C.; Mathijssen, Ron H. J.; de Wit, Ronald; van Weerden, Wytske M. (June 2015). "Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer". European Urology. 67 (6): 981–985. doi:10.1016/j.eururo.2014.11.033. ISSN 1873-7560. PMID 25484141.
  15. ^ Nieuweboer, Annemieke J. M.; de Morrée, Ellen S.; de Graan, Anne-Joy M.; Sparreboom, Alex; de Wit, Ronald; Mathijssen, Ron H. J. (July 2015). "Inter-patient variability in docetaxel pharmacokinetics: A review". Cancer Treatment Reviews. 41 (7): 605–613. doi:10.1016/j.ctrv.2015.04.012. ISSN 1532-1967. PMID 25980322.
  16. ^ de Morrée, Ellen; van Soest, Robert; Aghai, Ashraf; de Ridder, Corrina; de Bruijn, Peter; Ghobadi Moghaddam-Helmantel, Inge; Burger, Herman; Mathijssen, Ron; Wiemer, Erik; de Wit, Ronald; van Weerden, Wytske (July 2016). "Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation". The Prostate. 76 (10): 927–936. doi:10.1002/pros.23182. ISSN 1097-0045. PMID 26997363. S2CID 40934515.
  17. ^ Bellmunt, Joaquim; de Wit, Ronald; Vaughn, David J.; Fradet, Yves; Lee, Jae-Lyun; Fong, Lawrence; Vogelzang, Nicholas J.; Climent, Miguel A.; Petrylak, Daniel P.; Choueiri, Toni K.; Necchi, Andrea; Gerritsen, Winald; Gurney, Howard; Quinn, David I.; Culine, Stéphane (2017-03-16). "Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma". The New England Journal of Medicine. 376 (11): 1015–1026. doi:10.1056/NEJMoa1613683. ISSN 1533-4406. PMC 5635424. PMID 28212060.
  18. ^ Vuky, Jacqueline; Balar, Arjun V.; Castellano, Daniel; O'Donnell, Peter H.; Grivas, Petros; Bellmunt, Joaquim; Powles, Thomas; Bajorin, Dean; Hahn, Noah M.; Savage, Mary J.; Fang, Xiao; Godwin, James Luke; Frenkl, Tara L.; Homet Moreno, Blanca; de Wit, Ronald (2020-08-10). "Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer". Journal of Clinical Oncology. 38 (23): 2658–2666. doi:10.1200/JCO.19.01213. ISSN 1527-7755. PMID 32552471.
  19. ^ Gralla, Richard J.; de Wit, Ronald; Herrstedt, Jorn; Carides, Alexandra D.; Ianus, Juliana; Guoguang-Ma, Julie; Evans, Judith K.; Horgan, Kevin J. (2005-08-15). "Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: Analysis of combined data from two phase III randomized clinical trials". Cancer. 104 (4): 864–868. doi:10.1002/cncr.21222. ISSN 0008-543X. PMID 15973669.
  20. ^ Gralla, Richard J.; de Wit, Ronald; Herrstedt, Jorn; Carides, Alexandra D.; Ianus, Juliana; Guoguang-Ma, Julie; Evans, Judith K.; Horgan, Kevin J. (2005-08-15). "Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: Analysis of combined data from two phase III randomized clinical trials". Cancer. 104 (4): 864–868. doi:10.1002/cncr.21222. ISSN 0008-543X. PMID 15973669.
  21. ^ de Wit, Ronald; Freedland, Stephen J.; Oudard, Stephane; Marinov, Georgi; Capart, Philippe; Combest, Austin J.; Peterson, Ryan; Ozatilgan, Ayse; Morgans, Alicia K. (March 2023). "Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD". Prostate Cancer and Prostatic Diseases. 26 (1): 67–73. doi:10.1038/s41391-021-00487-1. ISSN 1476-5608. PMC 10023563. PMID 35039605.
  22. ^ de Wit, Ronald; Powles, Thomas; Castellano, Daniel; Necchi, Andrea; Lee, Jae-Lyun; van der Heijden, Michiel S.; Matsubara, Nobuaki; Bamias, Aristotelis; Fléchon, Aude; Sternberg, Cora N.; Drakaki, Alexandra; Yu, Evan Y.; Zimmermann, Annamaria H.; Long, Amanda; Walgren, Richard A. (July 2022). "Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy". British Journal of Clinical Pharmacology. 88 (7): 3182–3192. doi:10.1111/bcp.15233. ISSN 0306-5251. PMC 9302693. PMID 35029306.
  23. ^ de Wit, Ronald (2019-11-20). "Refinement of the Management of Germ Cell Cancer: What's Next?". Journal of Clinical Oncology. 37 (33): 3063–3065. doi:10.1200/JCO.19.02302. ISSN 0732-183X. PMID 31584840. S2CID 208400906.
  24. ^ de Wit, Ronald; de Bono, Johann; Sternberg, Cora N.; Fizazi, Karim; Tombal, Bertrand; Wülfing, Christian; Kramer, Gero; Eymard, Jean-Christophe; Bamias, Aristotelis; Carles, Joan; Iacovelli, Roberto; Melichar, Bohuslav; Sverrisdóttir, Ásgerður; Theodore, Christine; Feyerabend, Susan (2019-12-26). "Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer". New England Journal of Medicine. 381 (26): 2506–2518. doi:10.1056/NEJMoa1911206. hdl:2066/215761. ISSN 0028-4793. PMID 31566937.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ronald_de_Wit&oldid=1215244520"